



بسم الله الرحمن الرحيم

∞∞∞∞

تم رفع هذه الرسالة بواسطة / سلوي محمود عقل

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون أدنى

مسئولية عن محتوى هذه الرسالة.

ملاحظات: لا يوجد



Evaluation of PD-L1 Immunohistochemical Expression And Tumour Infiltrating Lymphocytes In Different Types Of Endometrial Carcinoma

Thesis

Submitted For Partial Fulfillment of M.D Degree in Pathology

By

Mariam Mahmoud Seleem El-Rashedy

M.B.B.CH, M.Sc. Ain Shams University

Supervised by

Professor / Ragaa Ahmed Salem

Professor of Pathology

Faculty of Medicine-Ain Shams University

Professor / Laila Nabegh Mohamed

Professor of Pathology

Faculty of Medicine-Ain Shams University

Professor / Riham Mohamed Abu-Zeid

Professor of Pathology

Faculty of Medicine-Ain Shams University

Professor / Nermine Mohamed Abd Raboh

Assistant Professor of Pathology

Faculty of Medicine-Ain Shams University

Faculty of Medicine

Ain Shams University

2022

Acknowledgment

In every step towards the completion of this work, I thank God for being beside me pushing me on his land to success and achievement.

I would like to express my deepest gratitude to **Professor / Ragaa Ahmed Salem** for her great support, supervision and scientific advices throughout this work.

And with all love and gratitude to **Professor / Laila Nabegh Mohamed** for her sincere reviewing and contributing to this work, helping me in the approach of each case teaching me the main principles of research work.

And my special thanks to **Professor / Riham Mohamed Abu-Zeid** for going with me every step reviewing and supporting this work devoting all her efforts for completion of all the details needed with ultimate accuracy.

With the whole gratitude goes to my dearest **Assistant Professor / Nermine Mohamed Abd Raboh** for her meticulous following of each step and reviewing the progress of the research work with all the passion and interest.

Finally , I owe many thanks to the **Department Of Pathology, Faculty Of Medicine, Ain Shams University** with all its staff members creating the best home for this work to arise.

Last but not least, from the bottom of my heart I would like to express my whole thanks to all the members of **Early cancer detection unit at Obstetric and Gynecology Ain shams University** for their continuous help and support and supply of materials needed for the accomplishment of this work .

List of contents:

Abstract	8
Introduction.....	9
Aim of work.....	13
Review of literature.....	14
Chapter (1).....	15
Chapter (2).....	65
Chapter (3).....	100
Material and methods.....	130
Results.....	137
Figures of thesis.....	164
Discussion.....	178
Conclusion and recommendation.....	184
References.....	186
Summary.....	237
Arabic summary.....	239

List of tables:

Table (1)	WHO (2014) Classification of uterine carcinomas
Table (2)	TNM and FIGO classification of carcinomas of the uterine endometrium
Table (3)	comparison of different types and grades of endometrial carcinoma
Table (4)	Age distribution of patients
Table (5)	Type of tissue biopsy
Table (6)	Gross appearance
Table (7)	Diagnosis
Table (8)	Grades
Table (9)	Myometrial invasion
Table (10)	Serosal involvement
Table (11)	Lymphovascular invasion
Table (12)	LNs involvement
Table (13)	Pd11 expression in tumor cells
Table (14)	PDL1 expression in TILs
Table (15)	Relation between Pd11 expression in tumor cells and Diagnosis
Table (16)	Relation between Pd11 expression in TILs and Diagnosis
Table (17)	Relation between Pd11 expression in tumor cells and Grades
Table (18)	Relation between Pd11 expression in TILs and Grades
Table (19)	Relation between Pd11 expression in tumor cells and extent of myometrial invasion
Table (20)	Relation between Pd11 expression in TILs cells and extent of myometrial invasion
Table (21)	Relation between Pd11 expression in tumor cells and serosal involvement
Table (22)	Relation between Pd11 expression in TILs cells and serosal involvement
Table (23)	Relation between Pd11 expression in tumor cells and lymphovascular invasion
Table (24)	Relation between Pd11 expression in tumor cells and lymphovascular invasion
Table (25)	Relation between Pd11 expression in tumor cells and lymph node involvement
Table (26)	Relation between Pd11 expression in TILs cells and lymph node involvement

List of graphs:

Graph (1)	types of tissue biopsies sampled.
Graph (2)	pie chart expressing the different gross appearance among the sample
Graph (3)	pie chart expressing the different diagnoses among the sample
Graph (4)	pie chart expressing the grades of diagnosed cases.
Graph (5)	pie chart expressing the myometrial invasion thickness in the excision biopsy cases
Graph (6)	pie chart showed serosal involvement in the sampled cases.
Graph (7)	pie chart expressing the myometrial invasion thickness in the excision biopsy cases
Graph (8)	pie chart showed nodal involvement in the sampled cases.
Graph (9)	pie chart showing the distribution of positive expression of PD-L1 in tumor cells with cut off value 5%
Graph (10)	pie chart showing the distribution of positive expression of PD-L1 in tumor cells with cut off value 10%.
Graph (11)	pie chart showing the distribution of positive expression of PD-L1 in TILs with cut off value 5%.
Graph (12)	pie chart showing the distribution of positive expression of PD-L1 in TILs with cut off value 10%.
Graph (13)	Bar chart showing the distribution of positive expression of PD-L1 in Tumor cells with cut off value (5 %) in Type I & II endometrial carcinomas.
Graph (14)	Bar chart showing the distribution of positive expression of PD-L1 in Tumor cells with cut off value (10 %) in Type I & II endometrial carcinomas.
Graph (15)	Bar chart showing the distribution of positive expression of PD-L1 in TILs with cut off value (5 %) in Type I & II endometrial carcinomas.
Graph (16)	Bar chart showing the distribution of positive expression of PD-L1 in TILs with cut off value (10 %) in Type I & II endometrial carcinomas.
Graph (17)	Bar chart showing the distribution of positive expression of PD-L1 in Tumor cells with cut off value (5 %) and (10%) in cases with different grades
Graph (18)	Bar chart showing the distribution of positive expression of PD-L1 in TILs cells with cut off value (5 %) and (10%) in cases with different grades
Graph (19)	Bar chart showing the distribution of positive expression of PD-L1 in Tumor cells with cut off value (5 %) and (10%) in cases showing different extent of myometrial invasion.
Graph (20)	Bar chart showing the distribution of positive expression of PD-L1 in TILs with cut off value (5 %) and (10%) in cases showing different extent of myometrial invasion.
Graph (21)	Bar chart showing the distribution of positive expression of PD-L1 in Tumor cells with cut off value (5 %) and (10%) in cases with positive and negative serosal involvement
Graph (22)	Bar chart showing the distribution of positive expression of PD-L1 in TILs cells with cut off value (5 %) and (10%) in cases with positive and negative

	serosal involment
Graph (23)	Bar chart showing the distribution of positive expression of PD-L1 in Tumor cells with cut off value (5 %) and (10%) in cases with positive and negative lymphovascular invasion
Graph (24)	Bar chart showing the distribution of positive expression of PD-L1 in TILs cells with cut off value (5 %) and (10%) in cases with positive and negative lymphovascular invasion
Graph (25)	Bar chart showing the distribution of positive expression of PD-L1 in Tumor cells with cut off value (5 %)and (10%) in cases with positive and negative lymph nodes involment.
Grapf (26)	Bar chart showing the distribution of positive expression of PD-L1 in TILs cells with cut off value (5 %)and (10%) in cases with positive and negative lymph nodes involment.

List of figures:

Fig (1)	Cancer immunoediting
Fig (2)	Immune checkpoints in the tumour microenvironment
Fig (3)	Immune checkpoints of immunosuppressive actions
Fig (4)	Cancer Therapy by Inhibition of Negative Immune Regulation (CTLA4, PD1)
Fig (5)	The PD-1/PD-L1 axis inhibits T cell activation, proliferation, and survival and cytotoxic secretion within cancer cell.
Fig (6)	A schematic representation illustrating the signalling molecules that are linked with or influenced by the programmed death 1 (PD-1)/ programmed death ligand 1 (PD-L1) interaction, as well as the cellular processes they affect
Fig. (7)	Inhibitors of PD-1/PD-L1 in cancers.
Fig (8)	CPS calculating method tumor method with staining
Fig (9)	TPS and CPS scoring system
Fig (10)	A case of low grade of Endometrioid carcinoma from hysterectomy specimen showing malignant glands with mild anaplastic cells (H&E stain x100)
Fig(11)	Low grade endometroid carcinoma showing negative PD-L1 staining of both tumor cells and tumor infiltrating lymphocytes (PD-L1 stain x100)
Fig (12)	Low grade endometroid carcinoma showing negative PD-L1 staining of both tumor cells and tumor infiltrating lymphocytes (PD-L1 stain x400)
Fig (13)	Low grade endometroid endometrial carcinoma showing positive staining of both tumor cells and tumor infiltrating lymphocytes. (PD-L1x40)
Fig (14)	Low grade endometroid endometrial carcinoma showing positive staining of >10% of both tumor cells and tumor infiltrating lymphocytes. (PD-L1x400)
Fig (15)	Low grade endometroid endometrial carcinoma showing positive staining of >10% of tumor cells in acini and invasive element. (PD-L1x400)
Fig (16)	A case of moderate grade endometroid endometrial carcinoma showing

	infiltration of the myometrium by malignant glands and solid sheets lined by cells showing moderate degree of anaplasia. (H&E x40)
Fig (17)	A moderate grade endometrioid endometrial carcinoma showed negative cytoplasmic staining in tumor cells and in infiltrating lymphocytes(PD-L1 x400).
Fig (18)	Moderate grade endometrioid endometrial carcinoma showing positive staining of tumor cells and tumor infiltrating lymphocytes. (PD-L1x100)
Fig (19)	High grade endometrioid endometrial carcinoma from an abdominal hysterectomy specimen showing solid sheets of high grade anaplastic cells(H&E stain x100)
Fig (20)	High grade endometrioid endometrial carcinoma from an abdominal hysterectomy specimen showing positive PD-L1 staining (PD-L1 stain x100)
Fig (21)	High grade endometrioid endometrial carcinoma showing solid positive PD-L1 tumor cells and tumor infiltrating lymphocytes. (PD-L1 stain x100)
Fig (22)	A case of clear cell endometrial carcinoma showing tumor cells with clear cytoplasm and anaplastic cells showing hobnail nucleus (H&E stain x100)
Fig (23)	Clear cell endometrial carcinoma showing tumor cells with clear cytoplasm and anaplastic cells showing hobnail nucleus with tumor infiltrating lymphocytes in the stroma inbetween the tumor cells (H&E stain x100)
Fig (24)	Clear cell endometrial carcinoma showing infiltration by tumor infiltrating lymphocytes and showing areas of necrosis. (H&Ex100)
Fig (25)	Clear cell endometrial carcinoma showing positive staining of both tumor cells and tumor infiltrating lymphocytes (PD-L1 x40)
Fig (26)	Clear cell endometrial carcinoma showing >10% positive staining of tumor cells. (PD-L1 stain x400)
Fig (27)	A case of serous carcinoma from a panhysterectomy specimen (H&E stain x40)
Fig (28)	Serous carcinoma from a panhysterectomy specimen showing the papillary structure of the tumor lined by high grade anaplastic cells(H&E stain x100)
Fig (29)	A case of serous carcinoma showing infiltration of the tumor tissue by few lymphocytic infiltrate (H&E stain x400)
Fig(30)	Serous carcinoma showing infiltration of the tumor tissue core by few lymphocytic infiltrate (H&E stain x400)
Fig (31)	Serous carcinoma showing positive staining of tumor cells and less than 5% of tumor infiltrating lymphocytes. (PD-L1x40)
Fig (32)	Positive PD-L1 staining of tumor cells of a case of serous carcinoma. (PD-L1 stain x100)
Fig (33)	Positive PD-L1 staining of both tumor cells and tumor infiltrating lymphocytes of a case of serous carcinoma. (PD-L1 stain x400)
Fig (34)	PD-L1 positivity in tumor emboli and malignant acini and in infiltrating lymphocytes. (PD-L1x400)

Abstract

Endometrial cancer (EC) identified at an early stage is successfully treated in a majority of patients with surgery with or without radiotherapy or chemotherapy. For patients with advanced disease, however, the prognosis is poor; 5-year survival rates are less than 50% in patients with lymph node metastases and less than 20% in those with peritoneal or distant metastases (*Herzog,2015*). Previous studies proved that PD1-/PD-L1 blockers are currently effectively used as immunotherapies in a number of tumors such as melanoma and non-small cell lung cancer. This study is conducted to determine the expression of PD-L1 in endometrial carcinoma and to assess its potential role as a biomarker for different types that can be used to screen candidates fit for immunotherapy. (**Gasparri,et al.,2017**)

